ArticleAmerican journal of translational research2025
ATP7A as a prognostic biomarker and potential therapeutic target in gastric cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Engineered bacteria reverses tumor cuproptosis resistance via cancer-associated fibroblast reprogramming for enhanced immunotherapy.Materials today. Bio · 2026Article
- ATP7A Orchestrates Tumor Progression and Cuproptosis in Hepatocellular Carcinoma via the LINC02038-miR-506-3p Regulatory Circuit.Journal of biochemical and molecular toxicology · 2026Article
- Targeting lung cancer: synergistic therapeutic strategy of cuproptosis and immunogenic cell death.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the roles of Cu transporter ATPase copper transporting alpha (ATP7A) in gastric cancer (GC) progression and prognosis.
methodsATP7A expression was investigated using databases, immunohistochemistry (IHC) and qPCR in tumor tissues and GC cell lines. Diagnostic and prognostic value of ATP7A was assessed by Receiver Operating Characteristic (ROC) and Kaplan-Meier curve, respectively. The roles of ATP7A were explored using protein-protein interaction (PPI), Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA), ssGSEA algorithm and Tumor Immune Estimation Resource (TIMER) databases. Subsequently, the effects of ATP7A were evaluated by Cell Counting Kit-8 (CCK-8), colony formation, and transwell assays.
resultsATP7A overexpression was associated with a higher IHC score and a larger area under the ROC curve (0.746). Elevated ATP7A expression correlated with shorter survival time, greater invasion depth of GC lesions, advanced pathological stages, and older age in GC patients. Comprehensive analysis revealed that ATP7A was involved in copper ion transport, transition metal ion homeostasis, cellular transition metal ion homeostasis, and copper ion homeostasis. Additionally, ATP7A was linked to key signaling pathways, including Hedgehog, Wnt/β-catenin, and Notch, along with the top 10 hub genes. Furthermore, ATP7A played a role in immune infiltration, influencing T cells, dendritic cells, B cells, macrophages, and neutrophils, as well as the expression of immune checkpoints such as Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), Programmed Cell Death Protein 1 Ligand 1 (PD-L1), T-Cell Immunoglobulin, and Mucin Domain-Containing Protein 3 (TIM-3). Experimental validation demonstrated that silencing ATP7A suppressed GC cell proliferation, colony formation, migration, and invasion.
conclusionATP7A promoted GC progression and acted as a promising prognostic target for the treatment of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.